Nanni, Oriana
Viale, Pierluigi
Vertogen, Bernadette http://orcid.org/0000-0002-5683-6363
Lilli, Claudia
Zingaretti, Chiara
Donati, Caterina
Masini, Carla
Monti, Manuela
Serra, Patrizia
Vespignani, Roberto
Grossi, Veruska
Biggeri, Annibale
Scarpi, Emanuela
Galardi, Francesca
Bertoni, Lucia
Colamartini, Americo
Falcini, Fabio
Altini, Mattia
Massa, Ilaria
Gaggeri, Raffaella
Martinelli, Giovanni
Article History
Received: 15 June 2020
Accepted: 16 June 2020
First Online: 31 July 2020
Ethics approval and consent to participate
: On 20<sup>th</sup> April 2020 this trial received the approval of the Ethics Committee (EC) of Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani-IRCCS, which is the national EC for COVID-19 trials. Informed consent will be obtained from participants prior to involvement in the trial. Given the extraordinary nature of the pandemic diffusion of COVID-19 and the safety measures set up to contain the spread of infection, it is not feasible to provide information to potentially eligible subjects through a face-to-face interview or to obtain informed consent signed in person by the subjects.Therefore, subjects will receive detailed information through a telephonic interview with a suitably qualified and experienced study physician and will then provide their consent through a web-based application. Written information about the study and informed consent forms will be made available through the study website. Whenever possible, a signed informed consent form will be obtained from subjects.Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy is the sponsor of this study.
: Not applicable.
: The authors declare that they have no competing interests.